Caplin Point Laboratories
CAPLIPOINT · Pharma > Pharmaceuticals & Drugs · Chairman: C C Paarthipan · MD: Sridhar Ganesan · Listing date: June 23, 2014 · Employees: 1675 · Chennai · http://www.caplinpoint.net

Stock Price vs Company Growth
1d
0.2%
1w
7.4%
1m
1.7%
3m
4.7%
6m
2.7%
1y
47.2%
5y
44.3%
10y
26.9%
all
45.4%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowSep07Mar11Sep14Mar18Sep21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

2,005 0.2%
1,551
2,109
Company Overview

Sales
1,937 Cr
Growth: 14.3%
Profit after Tax
536 Cr
Growth: 4.1%
Mid Cap
15,240 Cr
P/E: 28.3x
Industry P/E: 33.0x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 1,937
Growth 14.3%
EBITDA 33.4%
P/S 7.8x
Dividend 0.3%
P/E 28.3x
Book Value ₹ 375
PEG Ratio 2.0x
ROE 20.3%
P/B 5.3x
Shareholding Pattern

Institutions
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Mar22Jun22Mar23
Promoters
P Vijayalakhsmi
23.64 %
Paarthipan C C
18.73 %
Ashok Gorkey Partheeban
11.96 %
Partheeban Vivek Siddarth
11.9 %
May India Property Private Limited
2.8 %
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Mar22Jun22Mar23
Others
Iepf
2.46 %
Visalatchi
2.22 %
Suresh Kumar Agarwal
1.32 %
Ashish Kacholia
1.16 %
Llp
0.7 %
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Mar22Jun22Mar23
Increase    Decrease    No change
Company Profile Detailed

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.
Investors (51)
Followers (28)